Stock Events

Acadia Pharmaceuticals 

€22.6
3
-€0.2-0.88% Friday 07:22

Statistics

Day High
22.6
Day Low
22.6
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
2.8B
P/E Ratio
-12.89
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27FebConfirmed
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-0.43
-0.19
0.06
0.3
Expected EPS
0.3
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DR6.F. It's not an investment recommendation.

Analyst Ratings

34.92Average Price Target
The highest estimate is €42.
From 13 ratings within the last 6 months. This is not an investment recommendation.
Buy
69%
Hold
31%
Sell
0%

About

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Show more...
CEO
Mr. Stephen R. Davis
Employees
610
Country
US
ISIN
US0042251084
WKN
000603035

Listings